Physician profile
Michael Sofman
NPI 1508834458
$3,309.25
in general payments reported to CMS, 2019-2025
28 companies · $746 in 2025
The $746 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $201 · 2021: $271 · 2022: $342 · 2023: $620 · 2024: $863 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.76 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $650.85 | 2019-2025 | Tremfya, Remicade, Simponi |
| Abbvie INC. | $387.22 | 2019-2025 | Rinvoq |
| Amgen INC. | $354.61 | 2020-2025 | Otezla, Otezla |
| Genzyme Corporation | $326.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $264.33 | 2021-2025 | |
| Pfizer INC. | $208.51 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $182.04 | 2022-2025 | Libtayo, Dupixent |
| Mallinckrodt Hospital Products INC. | $161.83 | 2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $129.51 | 2023-2024 | Sotyktu |
| Ucb, INC. | $107.83 | 2022-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $56.02 | 2023-2024 | Ilumya |
| Elekta, INC. | $49.04 | 2025 | Flexitron Hdr |
| Celgene Corporation | $43.86 | 2019 | |
| Lilly USA, LLC | $43.35 | 2019-2022 | |
| Genentech USA, INC. | $40.95 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $37.22 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Verrica Pharmaceuticals INC. | $32.50 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $32.13 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.91 | 2019-2020 | |
| Incyte Corporation | $28.47 | 2025 | Opzelura |
| Strata Skin Sciences, INC. | $28.24 | 2023-2025 | Xtrac |
| Solta Medical, A Division of Bausch Health US, LLC | $24.60 | 2024 | Clear+Brilliant |
| Leo Pharma INC. | $19.28 | 2025 | Anzupgo |
| Sebela Pharmaceuticals INC. | $17.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $16.45 | 2024 | Tremfya |
| Almirall LLC | $15.28 | 2025 | Klisyri |
| Dermavant Sciences, INC. | $13.92 | 2023 | Vtama |
| Mayne Pharma Commercial LLC | $8.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sofman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.